| Literature DB >> 34462917 |
Catherine Diskin1, Kristina Malik2,3, Peter J Gill1,4,5,6, Nada Rashid7, Carol Y Chan4, Katherine E Nelson1,4,5, Joanna Thomson8,9, Jay Berry10,11, Rishi Agrawal11,12,13, Julia Orkin1,4, Eyal Cohen1,4,5,14,15.
Abstract
AIM: To identify the highest-priority clinical research areas related to children with neurological impairment and medical complexity among clinicians and caregivers.Entities:
Mesh:
Year: 2021 PMID: 34462917 PMCID: PMC9291325 DOI: 10.1111/dmcn.15037
Source DB: PubMed Journal: Dev Med Child Neurol ISSN: 0012-1622 Impact factor: 4.864
Figure 1Study rounds and results of the data collection and surveys. The steps required for the modified, three‐stage Delphi methodology using online surveys are shown. These led to the prioritization of clinical topics and research questions.
Round 2 prioritization of clinical topics (clinical experts [n=49] and family caregivers [n=12])
| Clinician prioritization | Caregiver prioritization | ||||||
|---|---|---|---|---|---|---|---|
| Rank | Clinical topic | Frequencya | Median (IQR) | Rank | Clinical topic | Frequency score | Median (IQR) |
| 1 | Irritability and pain | 28 | 6 (6–6.5) | 1 | Behavior | 40 | 7 (7–7) |
| 2 | Child mental health | 20 | 6 (4–6) | 2 | Acute LRTI | 37 | 6.5 (6–7) |
| 2 | Disorders of tone | 20 | 6 (5–7) | 3 | Enteral feeding tubes | 36 | 6 (5.25–6.75) |
| 2 | Polypharmacy | 20 | 5 (5–6) | 4 | Sleep | 35 | 5.5 (5–6.75) |
| 2 | Sleep | 20 | 5 (5–6) | 5 | Aspiration | 34 | 6 (6–6) |
| 3 | Aspiration | 19 | 6 (5–6.5) | 5 | Infection control | 34 | 6.5 (5.25–7) |
| 4 | Behavior | 18 | 5 (4–6.5) | 5 | Irritability and pain | 34 | 6.5 (5.25–7) |
| 4 | Dysautonomia | 18 | 5 (4–6) | 6 | Nutrition and growth | 33 | 5 (5–6.5) |
| 4 | Feeding tolerance | 18 | 5 (4–6.5) | 6 | Feeding tolerance | 33 | 6 (5.35–6) |
| 5 | Chronic lung disease | 13 | 5 (4–6) | 6 | Child mental health | 33 | 5.5 (5–6.75) |
| 6 | Nutrition and growth | 12 | 5 (3–6) | 7 | Chronic lung disease | 32 | 5.5 (4.25–6.75) |
| 7 | Acute LRTI | 11 | 5 (3–6) | 8 | Dysautonomia | 31 | 5.5 (4.25–6.75) |
| 8 | Enteral feeding tubes | 10 | 4 (3–5) | 9 | Constipation | 29 | 4 (3.5–6) |
| 8 | Sialorrhea | 10 | 5 (3.5–6) | 9 | GERD | 29 | 5 (3.25–6.75) |
| 8 | Scoliosis | 10 | 4 (3–5.5) | 9 | Polypharmacy | 29 | 5 (3.25–6) |
| 9 | Osteoporosis and osteopenia | 9 | 4 (4–6) | 10 | Sialorrhea | 28 | 5.5 (5.25–6) |
| 10 | Constipation | 8 | 4 (3–5) | 10 | Venous access | 28 | 4.5 (4–5) |
| 10 | Neurogenic bladder | 8 | 4 (3–5) | 11 | Disorders of tone | 27 | 4.5 (2.5–6.5) |
| 11 | GERD | 7 | 4 (4–6) | 11 | Postoperative complications | 27 | 4 (3.25–6.25) |
| 12 | Postoperative complications | 5 | 4 (3–5) | 11 | Peripubertal issues | 27 | 4.5 (2.5–6.5) |
| 12 | Infection control | 5 | 4 (3–5) | 12 | Neurogenic bladder | 26 | 4.5 (3.25–5) |
| 13 | Venous access | 4 | 3 (2–4) | 12 | Scoliosis | 26 | 4.5 (2.5–5.75) |
| 13 | Hip displacement | 4 | 4 (3–5) | 13 | Dental caries | 25 | 5.5 (2.25–5.75) |
| 14 | Hydrocephalus | 3 | 4 (2–5) | 14 | Hip displacement | 24 | 3.5 (2.25–3.25) |
| 14 | Peripubertal issues | 3 | 4 (2.5–5) | 14 | Hydrocephalus | 24 | 3.5 (2–5.75) |
| 15 | Dental caries | 2 | 4 (2.5–4.5) | 15 | Osteoporosis and osteopenia | 23 | 3.5 (2.25–4.75) |
The top clinical topics are shaded. aThe frequency score reflects the number of clinical experts who provided the top ranking for each clinical topic. IQR, interquartile range; LRTI, lower respiratory tract infection; GERD, gastroesophageal reflux disease.
Figure 2Frequency score of clinical topics by clinical experts. The frequency score calculated by the frequency of inclusion among the top seven of 26 clinical topics developed after round 1 is shown. LRTI, lower respiratory tract infection; GERD, gastroesophageal reflux disease.
Top 10 ranked research questions with related clinical topics
| Overall rank | Clinical topic | Research question | Total score | Median (IQR) |
|---|---|---|---|---|
| 1 | Feeding tolerance | In children with neurological impairment and medical complexity with feeding intolerance, do blenderized formulas (e.g. home or commercially) versus other formula (polymeric or hydrolyzed) improve outcomes (e.g. nutritional health, feeding tolerance, quality of life)? | 229 | 6 (5–7) |
| 2 | Disorders of tone | In children with neurological impairment and medical complexity with dystonia, does baclofen versus baclofen plus gabapentin improve outcomes (e.g. pain, function)? | 228 | 6 (5–6) |
| 3 | Dysautonomia | In children with neurological impairment and medical complexity with autonomic dysfunction, does propranolol versus gabapentin versus clonidine decrease symptoms of autonomic dysfunction (e.g. sweating, temperature dysregulation, blood pressure lability)? | 228 | 5 (5–7) |
| 4 | Irritability and pain | In children with neurological impairment and medical complexity with irritability, does gabapentin versus clonidine improve outcomes (e.g. duration of crying, discomfort)? | 227 | 6 (5–7) |
| 5 | Irritability and pain | In children with neurological impairment and medical complexity with irritability, does cannabidiol and/or tetrahydrocannabinol versus standard therapy (e.g. gabapentin) improve outcomes, for example, duration of crying, discomfort? | 226 | 6 (5–7) |
| 6 | Sleep | In children with neurological impairment and medical complexity with disrupted sleep, does melatonin versus hydroxyzine versus trazodone versus clonidine improve outcomes (e.g. sleep quality, sleep duration, daytime function)? | 225 | 6 (5–6) |
| 7 | Aspiration | In children with neurological impairment and medical complexity, does exclusive enteral (tube) feeding (without oral intake) versus a feeding plan, which includes oral intake, reduce aspiration risk? | 218 | 6 (4–7) |
| 8 | Feeding tolerance | In children with neurological impairment and medical complexity with feeding intolerance, does polymeric formula versus hydrolyzed formula improve outcomes (e.g. nutritional health, feeding tolerance, quality of life)? | 218 | 5 (4–7) |
| 9 | Child mental health | In children with neurological impairment and medical complexity, does screening for mental health issues versus standard (no screening) improve outcomes (e.g. child mental health)? | 217 | 5 (4–6) |
| 10 | Disorders of tone | In children with neurological impairment and medical complexity with dystonia not responsive to medication, does deep brain stimulation versus intrathecal baclofen improve outcomes (e.g. function)? | 216 | 5 (4–6) |
Two prioritized clinical topics did not have a research question ranked in the top 10 (polypharmacy and behavior). The top ranked question for the clinical topic of polypharmacy was ‘In CMC and neurological impairment, what are the demographics and clinical predictors of a medication error?’ (total score=185; median [IQR]=4 [3–6]). The top ranked question in the clinical topic of behavior was ‘In CMC and neurological impairment, what are the demographic and clinical predictors of challenging behavior (e.g. aggression) and emotional dysregulation?’ (total score=174; median [IQR]=4 [3–5]). IQR, interquartile range; CMC, children with medical complexity.